Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Capital Expenditures (2016 - 2025)

Celldex Therapeutics has reported Capital Expenditures over the past 16 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $1.3 million for Q4 2025, up 69.44% from a year ago — trailing twelve months through Dec 2025 was $2.7 million (up 41.43% YoY), and the annual figure for FY2025 was $2.7 million, up 41.43%.
  • Capital Expenditures for Q4 2025 was $1.3 million at Celldex Therapeutics, up from $440000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for CLDX hit a ceiling of $1.3 million in Q4 2025 and a floor of $143000.0 in Q2 2021.
  • Median Capital Expenditures over the past 5 years was $425000.0 (2023), compared with a mean of $476400.0.
  • Biggest five-year swings in Capital Expenditures: tumbled 84.29% in 2021 and later skyrocketed 370.63% in 2022.
  • Celldex Therapeutics' Capital Expenditures stood at $354000.0 in 2021, then tumbled by 33.62% to $235000.0 in 2022, then soared by 183.4% to $666000.0 in 2023, then grew by 13.51% to $756000.0 in 2024, then surged by 69.44% to $1.3 million in 2025.
  • The last three reported values for Capital Expenditures were $1.3 million (Q4 2025), $440000.0 (Q3 2025), and $728000.0 (Q2 2025) per Business Quant data.